Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025

Janux Therapeutics, Inc.

Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.
Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.
No successor or interim CSO announced; departure of named executive officer.

item 5.02

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-209259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.